Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06581848 | Korean Post Marketing Surveillance for ELREXFIO (Elranatamab). | active not recruiting | — | 150 | PfizerINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02253316 | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | active not recruiting | Phase 2 | 236 | Washington University School of MedicineOTHER | 1 | Nov 10, 2025 |
| clinicaltrials |
| NCT03315026 | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL(CHARKALL) | active not recruiting | Phase 1 | 54 | Baylor College of MedicineOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04459416 | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | active not recruiting | Phase 3 | 299 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05556720 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial(BOOST-IC) | active not recruiting | Phase 3 | 960 | Monash UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | active not recruiting | — | 200 | All4CureINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | active not recruiting | Phase 1 | 34 | AbbVieINDUSTRY | 4 | Aug 14, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | active not recruiting | Phase 2 | 120 | AbbVieINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088783 | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients(OCARE-MM) | active not recruiting | N/A | 60 | OzlemOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | active not recruiting | Phase 2 | 17 | Larysa SanchezOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT03421132 | Multiple Myeloma Molecular Monitoring Study(M4) | active not recruiting | — | 96 | Horizon Health NetworkOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03190525 | Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma(CLARITY) | active not recruiting | — | 530 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | active not recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04891809 | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | active not recruiting | Phase 2 | 198 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Apr 10, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT04392037 | Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone(ICON) | active not recruiting | Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients(SABLe) | active not recruiting | Phase 2 | 50 | Ida Bruun KristensenOTHER | 3 | Mar 18, 2025 | clinicaltrials |
| NCT06452446 | Telehealth-based Symptom Management for Veterans Treated With Selinexor(Selinexor) | active not recruiting | — | 20 | Durham VA Medical CenterFED | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 73 | US Oncology ResearchINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04786028 | A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM | active not recruiting | Phase 2 | 72 | Canadian Myeloma Research GroupOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT02315716 | Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma(Cardamon) | active not recruiting | Phase 2 | 281 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02406222 | Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)(MUKseven) | active not recruiting | Phase 2 | 124 | University of LeedsOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT02542657 | Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 30 | Joseph TuscanoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00048958 | Cytogenetic Studies in Acute Leukemia and Multiple Myeloma | active not recruiting | — | 9,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06366802 | Cohort Construction and Prognostic Model Construction for Multiple Myeloma | active not recruiting | — | 1,000 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04144387 | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.(CARRISMM) | active not recruiting | N/A | 395 | Intergroupe Francophone du MyelomeNETWORK | 3 | Mar 6, 2024 | clinicaltrials |
| NCT03915184 | Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | active not recruiting | Phase 1 / Phase 2 | 105 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant(ASCENT) | active not recruiting | Phase 2 | 87 | International Myeloma FoundationOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT06154902 | Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel(ABE-DESCART) | active not recruiting | — | 350 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2025source: clinicaltrials